Boa evolução da forma granulomatosa de Imunodeficiência Comum Variável
Good evolution of granulomatous form of the common variable immunodeficiency
Vivian A. G. Cunha; Caio C. S. Moises; Vinicius A. Naves; Patrícia Cristina L. Dionigi; Maria da Conceição S. de Menezes; Wilma Carvalho N. Forte
Resumo
sumo Objetivo: Descrever um caso de forma granulomatosa da imunodeficiência comum variável (ICV) enfatizando a boa evolução da doença granulomatosa durante o acompanhamento em longo prazo.
Descrição do caso: Paciente do gênero feminino, atualmente com 26 anos. Apresentava história de otites e amigdalites desde os seis meses e pneumonias desde os três anos de idade. Aos cinco anos foi levada a serviço especializado: apresentava-se desnutrida e com baço palpável a 9 cm e fígado a 2 cm. A investigação laboratorial iniciada nessa ocasião mostrou deficiência de IgG, IgA, IgM séricas, ausência de isohemaglutininas, linfócitos B, T, CD4+ e CD8+ normais. A biopsia hepática revelou doença granulomatosa. Foi então diagnosticada forma granulomatosa da ICV. A paciente foi submetida ao tratamento da imunodeficiência sendo indicado esteroide para a doença granulomatosa. O acompanhamento mensal da paciente durante 21 anos mostrou boa evolução, com regressão da hepatoesplenomegalia e preservação da função hepática.
Discussão: A ICV é uma deficiência primária predominantemente de anticorpos, em que há pneumonias de repetição e cujo tratamento principal é a reposição de gamaglobulina. A forma granulomatosa hepática da ICV é rara, mas deve ter diagnóstico precoce, na tentativa de preservar a função hepática. No presente caso, durante os 21 anos de acompanhamento, houve boa evolução da forma granulomatosa da imunodeficiência com o uso de baixas doses de esteroides.
Palavras-chave
Abstract
Objective: To describe a case of granulomatous form of common variable immunodeficiency (CVID) with good progress during a longterm monitoring.
Case report: Female patient, now 26. She had a history of ear infections and tonsillitis since she was six months and pneumonia as from the age of three years. At the age of five years she was taken to a specialized service: the patient was malnourished and with 9 cms palpable spleen and 2 cms liver. Laboratory investigation initiated at that time showed deficiency of IgG, IgA, IgM serum, absence of isohemaglutininas, and normal B, T, CD4+ and CD8+ lymphocytes. The liver biopsy revealed granulomatous disease. It was then diagnosed as granulomatous CVID. The patient was submitted to immunodeficiency treatment and steroid was indicated for the granulomatous disease. The patient’s monthly monitoring during 21 years showed good outcome, with regression of hepatosplenomegaly and preservation of liver function.
Discussion: CVID is predominantly a primary deficiency of antibodies, in which there is recurrent pneumonias and the main treatment recommended is the replacement of gammaglobulin. The granulomatous form of CVID is rare, nevertheless it must be diagnosed early so that the liver function can be preserved. In this 21-year-monitoring case there has been a good evolution of the granulomatous form of immunodeficiency with low doses of steroids.
Keywords
References
1. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010;116:7-15.
2. Blanco-Quirós A, Solís-Sánchez P, Garrote-Adrados JA, Arranz-Sanz E. Common variable immunodeficiency. Old questions are getting clearer. Allergol Immunopathol (Madr) 2006;34(6):263-75.
3. Llobet MP, Bertrán JM, Español T. Inmunodeficiencia común variable en la edad pediátrica. Allergol Immunopathol (Madr) 2002;30(1):42-6.
4. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet 2008;372(9637):489-502.
5. European Society of Immunodeficiencies. Disponível em: http://www.esid.org. Acessado em 31 de janeiro de 2012.
6. Rezaei N, Aghamohammadi A, Kardar G, Nourizadeh M, Pourpak Z. T- Helper 1 and 2 cytokine assay in patients with common variable immunodeficiency. J Investig Allergol Clin Immunol 2008;18(6):449-53.
7. Forte WCN, Carvalho Jr FF, Damaceno N, Perez FGV, Lopes CG, Mastrote RA. Evolution of IgA deficiency to IgG subclass deficiency and common variable immunodeficiency. Allergol Immunopathol (Madr) 2000;28:18-20.
8. Cunningham-Rundles C. Common variable immunodeficiency. Curr Allergy Asthma Rep 2001;1:421-9.
9. Kokron CM, Errante PR, Barros MT, Baracho GV, Camargo MM, Kalil J, et al. Clinical and laboratory aspects of common variable immunodeficiency. An Acad Bras Ciênc 2004;76(4):707-26.
10. Agondi RC, Toledo-Barros M, Kalil J, Giavina-Bianchi P. Pneumopatias em pacientes com imunnodeficiência comum variável. Rev bras alerg imunopatol 2009;32(3):84-8.
11. Modrzewska K, Wiatr E, Langfort R, Oniszh K, Roszkowski-Sliz K. Common variable immunodeficiency in a patient with suspected sarcoidosis. Pneumonol Alergol Pol 2009;77(1):91-6.
12. Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Dräger R, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003;4(3):261-8.
13. Warnatz K, Bossaller L, Salzer U, Skrabl-Baumgartner A, Schwinger W, van der BM, et al. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 2006;107:3045.
14. Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, SchmittGraeff A, Schlesier M, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37(8):820-8.
15. Spadaro G, D’Orio C, Genovese A, Galeotafiore A, D’Ambrosio C, Di Giovanni S, et al. Proteomic analysis of sera from common variable immunodeficiency patients undergoing replacement intravenous immunoglobulin therapy. J Biomed Biotechnol 2011;2011:706746.
16. Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol 2002;109:581-91.
17. Notarangelo LD. Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematology Am Soc Hematol Educ Program 2009;1:139-43.
18. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4):S525-53.
19. Knight AK, Radigan L, Marron T, Langs A, Zhang L, CunninghamRundles C. High serum levels of BAFF, APRIL and TACI in common variable immunodeficiency. Clin Immunol 2007;124(2):182-9.
20. Mrusek S, Marx A,Kümmerle-Deschner J, Tzaribachev N,Enders A, Riede U-N, et al. Development of granulomatous common variable immunodeficiency subsequent to infection with Toxoplasma gondii. Clin Exp Immunol 2004;137(3):578-83.
21. Aghamohammadi A, Abolhassani H, Rezaei N, Kalantari N, Tamizifar B, Cheraghi T, et al. Cutaneous granulomas in common variable immunodeficiency: case report and review of literature. Acta Dermatovenerol Croat 2010;18(2):107-13.
22. Moise A, Nedelcu FD, Toader MA, Sora SM, Tica A, Ferastraoaru DE, et al. Primary immunodeficiencies of the B lymphocyte. J Med Life 2010;3(1):60-3.
23. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008;28(1):S42-5.
24. Mechanic LJ, Dikman S, Cunnighm-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med 1997;127(8):1613-7.
25. García JM, Español T, Gurbindo MAD, Casas CC. Update on the treatment of primary immunodeficiencies. Allergol Immunopathol (Madr) 2007;35(5):184-92.
26. Kawakami K, Owan I, Kaneshima H, Saito A. Type 1-like helper T cell lines responsive to autologous peripheral blood monocytes established from two patients with sarcoidosis. Sarcoidosis 1995;12:111-7.
27. Drent M, Grutters JC, Mulder PG, van Velzen-Blad H, Wouters EF, van den Bosch JM. Is the different T helper cell activity in sarcoidosis and extrinsic allergic alveolitis also reflected by the cellular bronchoalveolar lavage fluid profile? Sarcoidosis Vasc Diffuse Lung Dis 1997;14:31-8.
28. Kunkel SL, Lukacs NW, Strieter RM, Chensue SW. Th1 and Th2 responses regulate experimental lung granuloma development. Sarcoidosis Vasc Diffuse Lung Dis 1996;13:120-8.
29. I Consenso Brasileiro sobre o uso de imunoglobulina humana em pacientes com imunodeficiências primárias. Rev bras alerg imunopatol 2010;33:104-16.
30. Forte WCN. Resposta imunológica a agentes infecciosos. In: Forte WCN. Imunologia do básico ao aplicado. 2ª. ed. Porto Alegre: Artmed Editora. 2007.p.343-57.
31. Costa-Carvalho BT, Wandalsen GF, Pulici G, Aranda CS, Solé D. Pulmonary complications in patients with antibody deficiency. Allergol Immunopathol (Madr) 2011;39(3):128-32.
32. Ameratunga R, Becroft DM, Hunter W. The simultaneous presentation of sarcoidosis and common variable immune deficiency. Pathology 2000;32(4):280-2.
33. Salzer U, Grimbacher B. Common variable immunodeficiency: The power of co-stimulation. Semin Immunol 2006,18:337-46.
34. Gonzalez-Granado LI. Multiple faces of sarcoidosis mimicking an underlying disease: don’t forget immunoglobulin G. South Med J 2009;102(12):1281-6.
35. Chapel H,Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009;145(6):709-27.
Submitted date:
12/21/2011
Accepted date:
04/02/2012
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email